Skip to main content
SpringerLink
Log in

Surgical Management of Hypertrophic Cardiomyopathy

  • Chapter
Surgical Management of Congestive Heart Failure

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 593 Accesses

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by ventricular hypertrophy in the absence of an identifiable cause for the hypertrophy (1–4). The hypertrophy is usually asymmetric and involves the interventricular septum in 90% of patients. Most commonly, the outflow septum (i.e., subaortic area) is the major focus of hypertrophy, but the midventricular or apical septum may occur in isolation or concomitantly. Rarely (5%) the right ventricle is involved. The extent of the hypertrophy varies tremendously and accounts for different manifestations of the disease (1–5). The hypertrophy is associated with myocardial fiber disarray on microscopy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;92:1680–1692.

    PubMed  CAS  Google Scholar 

  2. Spirito P, Sideman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–785.

    Article  PubMed  CAS  Google Scholar 

  3. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–133.

    Article  PubMed  CAS  Google Scholar 

  4. Maron BJ, Salberg L. Hypertrophic Cardiomyopathy: For Patients, Their Families, and Interested Physicians. Futura, New York: 2001.

    Google Scholar 

  5. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–655.

    Article  PubMed  CAS  Google Scholar 

  6. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy. Long QT syndrome, and Marfan syndrome. Circulation 1998;98:1460–1471.

    CAS  Google Scholar 

  7. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocar-diographic analysis of 4111 subjects in the CARDIA study. Circulation 1995;92:785–789.

    PubMed  CAS  Google Scholar 

  8. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and extent of the hypertrophy. A review. Prog Cardiovasc Dis 1985;28:l–83.

    Article  Google Scholar 

  9. Hecht GM, Panza JA, Maron BJ. Clinical course of middle-aged asymptomatic patients with hypertrophic cardiomyopathy. Am J Cardiol 1992;69:935–940.

    Article  PubMed  CAS  Google Scholar 

  10. Yetman A, Hamilton R, Benson L, McCrindle BW. Factors associated with outcome in children with hypertrophic cardiomyopathy. Can J Cardiol 1997;13:88C.

    Google Scholar 

  11. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy—a risk factor for sudden death. N Engl J Med 1998;339:1201–1209.

    Article  PubMed  CAS  Google Scholar 

  12. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778–1785.

    Article  PubMed  CAS  Google Scholar 

  13. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 2000;102:858–864.

    PubMed  CAS  Google Scholar 

  14. Doevendans PA. Hypertrophic cardiomyopathy: do we have the algorithm for life and death? Circulation 2000;101:1224–1226.

    PubMed  CAS  Google Scholar 

  15. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons < 40 years of age. Am J Cardiol 1991;68:1388–1392.

    Article  PubMed  CAS  Google Scholar 

  16. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743–2747.

    PubMed  CAS  Google Scholar 

  17. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patient. J Am Coll Cardiol 2000;36:2212–2218.

    Article  PubMed  CAS  Google Scholar 

  18. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989;80:1489–1492.

    PubMed  CAS  Google Scholar 

  19. Elliott PM, Sharma S, Varnava A, Poloniecki J, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–1601.

    Article  PubMed  CAS  Google Scholar 

  20. Wigle ED, Rakowski H. Hypertrophic cardiomyopathy: when do you diagnose midventricular obstruction vs apical cavity obliteration with a small nonobliterated area at the apex of the left ventricle? J Am Coll Cardiol 1992;19:525–526.

    PubMed  CAS  Google Scholar 

  21. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992;20:53–54.

    Google Scholar 

  22. Yu E, Chiam C, Siu S, Rakowski H, Wigle ED, O’Kelly B. Left atrial structure and function post myectomy in patients with hypertrophic obstructive cardiomyopathy. Can J Cardiol 1997;13:95C.

    Google Scholar 

  23. Yu EHC, Omran AS, Wigle D, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000;36:2219–2225.

    Article  PubMed  CAS  Google Scholar 

  24. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412–416.

    Article  PubMed  CAS  Google Scholar 

  25. Gilligan DM, Missouris CG, Boyd MJ, Oakley CM. Sudden death due to ventricular tachycardia during Amiodarone therapy in familial hypertrophic cardiomyopathy. Am J Cardiol 1991;68:971–973.

    Article  PubMed  CAS  Google Scholar 

  26. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365–373.

    Article  PubMed  CAS  Google Scholar 

  27. McDonald K, McWilliams E, O’Keefe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J 1988;9:893–898.

    PubMed  CAS  Google Scholar 

  28. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 1999;99:2927–2933.

    PubMed  CAS  Google Scholar 

  29. Williams WG, Wigle ED, Rakowski H, Smallhorn J, Leblanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987;76:V104–V108.

    PubMed  CAS  Google Scholar 

  30. Williams WG, Ralph-Edwards AC, Wigle ED. Surgical management of hypertrophic obstructive cardiomyopathy. Cardiol Rev 1997;5:40–49.

    Article  Google Scholar 

  31. Theodora DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg 1996;112:1589–1599.

    Article  Google Scholar 

  32. Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995;110:195–208.

    Article  PubMed  CAS  Google Scholar 

  33. McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1999;99:2927–2933.

    Google Scholar 

  34. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance of intraoperative decision making. J Am Coll Cardiol 1992;53:42–52.

    Article  Google Scholar 

  35. Cregg N, Cheng DCH, Karski JM, Williams WG, Webb G, Wigle ED. Morbidity outcome in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac septal myectomy: early-extubation anesthesia vs high-dose opioid anesthesia technique. J Cardiothorac Vase Anesthesia 1999;13:47–52.

    Article  CAS  Google Scholar 

  36. Sigwart U. Nonsurgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211–214.

    Article  PubMed  CAS  Google Scholar 

  37. Faber L, Seggewiss H, Fassbender D, et al. Identification of the target vessel (TV) in percutaneous transluminal ablation (PTSMA) in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography (MCE) [abstract]. Circulation 1997;96(suppl I):I–639.

    Google Scholar 

  38. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH, Nagueh SF. Echocardiographic insight into the mechanisms of relief of left ventricular obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;37:208–214.

    Article  PubMed  CAS  Google Scholar 

  39. Woo A, Schwartz L, Wigle ED, Ross J, Rakowski H. Myocardial contrast echocardiography during septal ethanol ablation for obstructive hypertrophic cardiomyopathy. In: Goldberg BB, Raichlen JS, Forsberg F, eds. Ultrasound Contrast Agents. Martin Dunitz: 2000, pp. 197–211.

    Google Scholar 

  40. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103:1492–1496.

    PubMed  CAS  Google Scholar 

  41. Li G, Li R-K, Mickle DAG, et al. Elevated insulin-like growth factor-1 and transforming growth factor-BI and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy. Circulation 1998;98:II-144–II-150.

    CAS  Google Scholar 

  42. Li G, Li R-K, Borger MA, et al. Regional overexpression of IGF-1 and TGF-B1 in the myocardium of hypertrophic obstructive cardiomyopathy patients. J Thorac Cardiovasc Surg 2002;123:89–95.

    Article  PubMed  CAS  Google Scholar 

  43. Seggewiss H, Gleichman U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3 month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252–258.

    Article  PubMed  CAS  Google Scholar 

  44. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000;355:425–426.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Surgery, Department of Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

    William G. Williams MD

  2. Division of Cardiovascular Surgery, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

    E. Douglas Wigle MD

  3. Division of Cardiovascular Surgery, University of Toronto, Toronto, Ontario, Canada

    Harry Rakowski MD, Anthony C. Ralph-Edwards MD & Leonard Schwartz MD

Authors
  1. William G. Williams MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Douglas Wigle MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harry Rakowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony C. Ralph-Edwards MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leonard Schwartz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    James C. Fang MD  & Gregory S. Couper MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Williams, W.G., Wigle, E.D., Rakowski, H., Ralph-Edwards, A.C., Schwartz, L. (2005). Surgical Management of Hypertrophic Cardiomyopathy. In: Fang, J.C., Couper, G.S. (eds) Surgical Management of Congestive Heart Failure. Contemporary Cardiology. Humana Press. https://doi.org/10.1385/1-59259-842-0:203

Download citation

  • DOI: https://doi.org/10.1385/1-59259-842-0:203

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-034-2

  • Online ISBN: 978-1-59259-842-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation